7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 
      
    		                            
      assets
    		                            
      current assets:
    		                            
      cash and cash equivalents
    		201,249,000 59,187,000 110,552,000 74,006,000 43,769,000 46,520,000 91,542,000 109,284,000 144,674,000 25,976,000 87,335,000 91,979,000 210,477,000 247,790,000 302,655,000 278,306,000 452,097,000 341,378,000 281,278,000 266,143,000 405,238,000 151,197,000 212,738,000 54,893,000 63,946,000 213,394,000 165,192,000 61,521,000 
      restricted cash
    		34,727,000 6,583,000 7,868,000 4,339,000 5,853,000 5,097,000 7,565,000 5,298,000 6,395,000 9,251,000 8,556,000 6,203,000 6,068,000 8,949,000 7,964,000 4,847,000 3,717,000 5,743,000 2,372,000 2,129,000 1,687,000 1,625,000 4,320,000 2,129,000 2,797,000 5,385,000 7,001,000 7,069,000 
      trade accounts receivable
    		885,199,000 754,236,000 775,731,000 748,055,000 769,871,000 668,955,000 613,732,000 674,736,000 545,760,000 741,791,000 628,737,000 688,849,000 538,309,000 662,583,000 627,954,000 652,015,000 530,600,000 638,895,000 707,103,000 582,734,000 722,682,000 604,390,000 518,109,000 634,666,000 640,212,000 481,495,000 641,029,000 626,491,000 
      inventories
    		614,500,000 601,433,000 612,454,000 596,359,000 575,624,000 570,653,000 581,384,000 550,558,000 529,042,000 530,735,000 543,858,000 533,028,000 512,241,000 489,389,000 520,245,000 523,385,000 497,008,000 490,649,000 475,760,000 443,956,000 437,959,000 381,067,000 401,827,000 414,627,000 448,294,000 457,219,000 490,768,000 512,479,000 
      prepaid expenses and other current assets
    		101,511,000 88,524,000 80,717,000 81,956,000 81,596,000 87,298,000 82,685,000 81,764,000 81,424,000 103,565,000 149,650,000 232,204,000 121,408,000 110,218,000 110,212,000 103,798,000 75,137,000 73,467,000 76,264,000 184,748,000 204,409,000 70,164,000 66,699,000 77,062,000 111,563,000 128,321,000 126,386,000 139,596,000 
      related party receivables
    		1,292,000 487,000 484,000 8,579,000 8,767,000 1,521,000 955,000 149,000 30,000 500,000 1,696,000 1,338,000 1,175,000 1,179,000 1,307,000 1,124,000 1,102,000 1,407,000 942,000 1,164,000 1,725,000 1,767,000 2,138,000 2,470,000 1,156,000 830,000 925,000 738,000 
      total current assets
    		1,838,478,000 1,510,450,000 1,587,806,000 1,513,294,000 1,485,480,000 1,380,044,000 1,377,863,000 1,421,789,000 1,307,325,000 1,411,818,000 1,419,832,000 1,553,601,000 1,389,678,000 1,520,108,000 1,570,337,000 1,563,475,000 1,559,661,000 1,551,539,000 1,543,719,000 1,480,874,000 1,773,700,000 1,210,210,000 1,205,831,000 1,185,847,000 1,267,968,000 1,286,644,000 1,431,301,000 1,347,894,000 
      property, plant and equipment
    		434,991,000 427,231,000 424,908,000 431,020,000 425,380,000 439,815,000 447,574,000 459,108,000 462,606,000 469,815,000 470,150,000 483,625,000 500,911,000 514,158,000 459,651,000 468,415,000 471,165,000 477,754,000 462,438,000 460,528,000 467,559,000 477,997,000 490,712,000 508,086,000 514,414,000 544,146,000 567,498,000 569,328,000 
      goodwill
    		595,945,000 597,497,000 597,436,000 598,324,000 598,533,000 598,549,000 598,629,000 599,206,000 599,156,000 598,853,000 599,504,000 600,974,000 602,893,000 593,017,000 566,406,000 549,091,000 522,758,000 522,814,000 522,690,000 527,475,000 514,733,000 419,504,000 419,671,000 420,017,000 421,640,000 426,226,000 410,616,000 386,475,000 
      intangible assets
    		587,938,000 689,136,000 732,377,000 780,189,000 819,944,000 859,272,000 890,423,000 1,015,376,000 1,055,319,000 1,096,093,000 1,159,005,000 1,204,224,000 1,209,818,000 1,166,922,000 1,232,727,000 1,293,325,000 1,262,954,000 1,304,626,000 1,349,113,000 1,423,826,000 1,475,161,000 1,382,753,000 1,435,801,000 1,553,330,000 1,591,158,000 1,654,969,000 1,733,020,000 1,788,533,000 
      operating lease right-of-use assets
    		31,769,000 29,103,000 31,388,000 32,872,000 33,284,000 32,970,000 30,329,000 34,031,000 36,127,000 38,211,000 34,252,000 36,490,000 37,675,000 39,899,000 38,993,000 41,065,000 32,396,000 33,947,000 43,643,000 49,159,000 50,943,000 53,344,000 56,455,000 59,900,000 63,238,000    
      operating lease right-of-use assets - related party
    		16,875,000 10,447,000 10,964,000 11,473,000 11,974,000 12,468,000 12,954,000 16,566,000 17,244,000 17,910,000 18,566,000 19,212,000 19,846,000 20,471,000 21,085,000 21,689,000 24,110,000 24,792,000 25,463,000 26,183,000 21,616,000 16,528,000 14,930,000 17,031,000 17,565,000    
      financing lease right-of-use assets
    		54,420,000 55,967,000 56,433,000 57,532,000 58,299,000 59,532,000 59,280,000 61,570,000 62,400,000 63,424,000 64,468,000 63,443,000 64,204,000 64,475,000 65,682,000 66,777,000 67,465,000            
      other assets
    		39,458,000 45,418,000 60,133,000 36,274,000 77,028,000 73,747,000 55,517,000 93,240,000 86,428,000 103,217,000 108,262,000 79,836,000 63,943,000 20,614,000 19,528,000 19,216,000 19,561,000 31,885,000 31,142,000 28,731,000 26,456,000 44,270,000 18,607,000 63,459,000 62,422,000 67,592,000 73,642,000 78,653,000 
      total assets
    		3,599,874,000 3,365,249,000 3,501,445,000 3,460,978,000 3,509,922,000 3,456,397,000 3,472,569,000 3,700,886,000 3,626,605,000 3,799,341,000 3,874,039,000 4,041,405,000 3,888,968,000 3,939,664,000 3,974,409,000 4,023,053,000 3,960,070,000 4,006,033,000 4,037,536,000 4,056,756,000 4,390,800,000 3,665,890,000 3,703,943,000 4,262,139,000 4,384,586,000 4,352,736,000 4,582,048,000 4,544,588,000 
      liabilities and stockholders’ deficiency
    		                            
      current liabilities:
    		                            
      accounts payable and accrued expenses
    		731,825,000 628,572,000 735,450,000 671,085,000 619,194,000 558,518,000 534,662,000 512,719,000 467,421,000 538,199,000 531,462,000 561,692,000 539,734,000 583,345,000 589,412,000 596,227,000 574,322,000 613,661,000 613,619,000 599,489,000 606,925,000 507,483,000 495,857,000 505,143,000 558,750,000 514,440,000 513,122,000 555,634,000 
      current portion of liabilities for legal matters
    		40,598,000 43,503,000 31,755,000 30,181,000 30,740,000 30,130,000 76,988,000 77,011,000 76,317,000 107,483,000 176,094,000 275,338,000                 
      revolving credit facility
    		 290,000,000 100,000,000 140,000,000 179,000,000 179,000,000 179,000,000  100,000,000 60,000,000 60,000,000 85,000,000         300,000,000        
      current portion of long-term debt
    		7,202,000 31,790,000 224,213,000 224,692,000 225,156,000 33,660,000 34,125,000 30,405,000 29,965,000 29,961,000 29,940,000 29,920,000 30,523,000 30,614,000 30,471,000 30,461,000 29,817,000 44,228,000 29,776,000 29,756,000 29,736,000 21,479,000 21,468,000 21,445,000 21,445,000 21,449,000  21,427,000 
      current portion of operating lease liabilities
    		7,985,000 8,986,000 9,435,000 9,702,000 9,669,000 9,508,000 9,207,000 9,861,000 9,017,000 8,321,000 10,266,000 10,096,000 9,901,000 9,686,000 9,180,000 8,237,000 6,637,000 6,474,000 11,527,000 12,512,000 12,125,000 11,874,000 13,467,000 13,313,000 13,173,000    
      current portion of operating lease liabilities - related party
    		2,826,000 3,449,000 3,396,000 3,327,000 3,259,000 3,192,000 2,825,000 2,992,000 2,930,000 2,869,000                   
      current portion of financing lease liabilities
    		3,458,000 3,319,000 3,211,000 3,300,000 3,199,000 3,305,000 2,467,000 3,219,000 3,309,000 3,488,000 3,557,000 3,318,000 3,233,000 3,101,000 3,218,000 2,806,000 3,020,000            
      related party payables - short term
    		68,212,000 66,205,000 22,311,000 12,922,000 12,773,000 17,075,000 7,321,000 21,143,000 14,750,000 2,479,000 3,867,000 24,904,000 15,960,000 47,861,000    7,561,000           
      total current liabilities
    		862,106,000 1,075,824,000 1,129,771,000 1,095,209,000 1,114,353,000 834,388,000 846,595,000 777,350,000 703,709,000 752,800,000 817,995,000 993,064,000 602,043,000 677,243,000 667,335,000 672,862,000 636,779,000 676,902,000 667,886,000 655,019,000 965,065,000 550,406,000 534,910,000 546,159,000 599,530,000 553,850,000 749,271,000 669,736,000 
      long-term debt
    		2,566,500,000 2,153,979,000 2,161,790,000 2,169,607,000 2,177,578,000 2,377,707,000 2,386,004,000 2,549,177,000 2,561,724,000 2,591,981,000 2,607,217,000 2,622,447,000 2,672,661,000 2,680,053,000 2,687,668,000 2,720,117,000 2,728,212,000 2,735,264,000 2,757,139,000 2,764,578,000 2,772,029,000 2,609,046,000 2,614,412,000 2,619,788,000 2,625,152,000 2,630,598,000  2,641,305,000 
      operating lease liabilities
    		26,405,000 22,854,000 24,814,000 26,210,000 26,782,000 26,786,000 24,095,000 28,296,000 30,782,000 32,126,000 26,366,000 28,904,000 30,378,000 32,894,000 32,562,000 34,723,000 28,435,000 30,182,000 34,849,000 38,591,000 40,615,000 43,135,000 44,375,000 47,836,000 51,200,000    
      operating lease liabilities - related party
    		15,676,000 8,520,000 9,391,000 10,265,000 11,126,000 11,969,000 12,787,000 14,388,000 15,163,000 15,914,000 16,653,000 17,380,000 18,093,000 18,783,000 19,462,000 20,131,000 22,308,000 23,049,000 23,777,000 24,478,000 19,874,000 15,469,000 14,271,000 14,862,000 15,445,000    
      financing lease liabilities
    		55,672,000 56,604,000 56,889,000 57,558,000 58,007,000 58,809,000 58,566,000 59,836,000 60,241,000 60,769,000 61,311,000 60,011,000 60,286,000 60,251,000 60,966,000 61,643,000 61,871,000            
      related party payables - long term
    		8,587,000 10,687,000  26,186,000 16,146,000 11,394,000  9,123,000 11,207,000  10,296,000 10,654,000 10,371,000                
      liabilities for legal matters - long term
    		74,477,000 72,979,000 85,479,000 85,479,000 85,479,000 85,479,000                       
      other long-term liabilities
    		32,626,000 23,191,000 26,949,000 24,144,000 24,518,000 24,579,000 29,995,000 39,282,000 41,456,000 87,468,000 78,258,000 79,213,000 32,866,000 38,903,000 60,795,000 63,255,000 63,789,000 85,683,000 96,188,000 93,772,000 80,846,000 39,583,000    38,780,000 44,769,000 45,667,000 
      total long-term liabilities
    		2,779,943,000 2,348,814,000 2,416,212,000 2,399,449,000 2,399,636,000 2,638,616,000 2,564,670,000 2,740,662,000 2,760,701,000 2,837,613,000 2,839,380,000 2,857,465,000 2,863,098,000 2,878,541,000 2,908,648,000 2,945,807,000 2,943,504,000 2,972,395,000 3,009,522,000 3,018,341,000 3,009,714,000 2,768,696,000 2,773,309,000 2,966,628,000 2,985,275,000 2,902,523,000 2,917,458,000 2,923,508,000 
      commitments and contingencies
    		                            
      redeemable non-controlling interests
    		67,780,000 72,611,000 64,974,000 59,887,000 53,422,000 47,022,000 41,293,000 32,106,000 27,527,000 24,949,000 22,375,000 17,885,000 16,420,000 16,907,000 15,260,000 14,112,000 13,079,000  11,932,000 12,380,000 12,563,000        
      stockholders’ deficiency
    		                            
      preferred stock, 0.01 par value, 2,000 shares authorized at both september 30, 2025 and december 31, 2024; none issued at both september 30, 2025 and december 31, 2024
    		                            
      class a common stock
    		3,143,000 3,134,000 3,099,000 3,098,000 3,095,000 3,086,000 3,066,000 1,540,000 1,532,000 1,514,000 1,513,000 1,510,000 1,506,000 1,492,000 1,492,000 1,490,000 1,485,000 1,475,000 1,475,000 1,474,000 1,472,000 1,470,000 1,340,000 1,281,000 1,156,000 1,151,000 1,150,000 1,149,000 
      class b common stock
    		       1,522,000 1,522,000 1,522,000 1,522,000 1,522,000 1,522,000 1,522,000 1,522,000 1,522,000 1,522,000 1,522,000 1,522,000 1,522,000 1,522,000 1,522,000 1,651,000 1,710,000 1,710,000 1,713,000 1,713,000 1,713,000 
      additional paid-in capital
    		563,363,000 545,806,000 560,206,000 553,233,000 545,701,000 538,720,000 539,240,000 708,233,000 700,722,000 691,629,000 683,745,000 675,588,000 666,799,000 658,350,000 650,539,000 642,657,000 634,484,000 628,413,000 623,133,000 617,504,000 611,600,000 606,966,000 565,641,000 544,161,000 537,159,000 530,438,000 520,160,000 517,122,000 
      stockholders' accumulated deficit
    		-570,081,000 -594,867,000 -607,062,000 -575,981,000 -575,825,000 -581,819,000 -490,176,000 -401,209,000 -413,126,000 -406,183,000 -401,850,000 -399,161,000 -278,353,000  -269,820,000 -265,583,000 -280,115,000 -286,821,000 -283,784,000 -274,809,000 -262,813,000 -377,880,000 -345,752,000 -80,746,000 -63,844,000 -20,920,000 -12,152,000 -19,104,000 
      accumulated other comprehensive loss
    		-105,883,000 -85,740,000 -65,510,000 -73,782,000 -30,436,000 -23,711,000       -349,000 -24,827,000 -33,227,000 -33,979,000 -34,361,000 -41,318,000 -41,306,000 -39,696,000 -33,405,000 -68,000 -4,879,000 -6,750,000 -4,099,000 -7,755,000   
      total amneal pharmaceuticals, inc. stockholders’ deficiency
    		-109,458,000 -131,667,000                           
      non-controlling interests
    		-497,000 -333,000 -245,000 -135,000 -24,000 95,000 230,000 -167,401,000 -159,746,000 -114,442,000 -103,180,000 -107,336,000 16,282,000 6,633,000 32,660,000 44,165,000 43,693,000 41,661,000 47,156,000 65,021,000 85,082,000 114,778,000 177,723,000 289,696,000 327,576,000 391,613,000 414,214,000 444,985,000 
      total stockholders' deficiency
    		-109,955,000 -132,000,000                           
      total liabilities and stockholders’ deficiency
    		3,599,874,000 3,365,249,000                           
      preferred stock, 0.01 par value, 2,000 shares authorized at both march 31, 2025 and december 31, 2024; none issued at both march 31, 2025 and december 31, 2024
    		                            
      liabilities and stockholders’ (deficiency) equity
    		                            
      note payable - related party
    		     41,893,000 41,447,000 40,560,000 40,128,000 39,706,000 39,279,000 38,856,000 38,443,000 38,038,000 37,629,000 37,224,000 36,828,000 36,440,000 36,048,000 35,661,000 35,281,000        
      related party payable - long term
    		  50,900,000    11,776,000   9,649,000    9,619,000 9,566,000 8,714,000 2,061,000 1,584,000 1,031,000 479,000         
      stockholders’ (deficiency) equity:
    		                            
      preferred stock, 0.01 par value, 2,000 shares authorized at december 31, 2024 and 2023; none issued at both december 31, 2024 and 2023
    		                            
      total amneal pharmaceuticals, inc. stockholders' (deficiency) equity
    		  -109,267,000 -93,432,000 -57,465,000 -63,724,000                       
      total stockholders' (deficiency) equity
    		  -109,512,000 -93,567,000 -57,489,000 -63,629,000                       
      total liabilities and stockholders' (deficiency) equity
    		  3,501,445,000 3,460,978,000 3,509,922,000 3,456,397,000                       
      liabilities and stockholders' (deficiency) equity
    		                            
      stockholders' (deficiency) equity
    		                            
      preferred stock, 0.01 par value, 2,000 shares authorized at both september 30, 2024 and december 31, 2023; none issued at both september 30, 2024 and december 31, 2023
    		                            
      current portion of notes payable - related party
    		    31,363,000                        
      preferred stock, 0.01 par value, 2,000 shares authorized at both june 30, 2024 and december 31, 2023; none issued at both june 30, 2024 and december 31, 2023
    		                            
      preferred stock, 0.01 par value, 2,000 shares authorized at both march 31, 2024 and december 31, 2023; none issued at both march 31, 2024 and december 31, 2023
    		                            
      liabilities and stockholders’ equity
    		                            
      stockholders’ equity:
    		                            
      preferred stock, 0.01 par value, 2,000 shares authorized; none issued at both december 31, 2023 and 2022
    		                            
      accumulated other comprehensive income
    		      -32,349,000 8,083,000 3,764,000 9,939,000 12,539,000 868,000                 
      total amneal pharmaceuticals, inc. stockholders' equity
    		      19,781,000 318,169,000 294,414,000 298,421,000 297,469,000 280,327,000 391,125,000  350,506,000 346,107,000 323,015,000 303,271,000 301,040,000 305,995,000 318,376,000 232,010,000 218,001,000 459,656,000 472,205,000 504,750,000   
      total stockholders' equity
    		      20,011,000 150,768,000 134,668,000 183,979,000 194,289,000 172,991,000 407,407,000  383,166,000 390,272,000 366,708,000 344,932,000 348,196,000 371,016,000 403,458,000 346,788,000 395,724,000 749,352,000 799,781,000 896,363,000   
      total liabilities and stockholders' equity
    		      3,472,569,000 3,700,886,000 3,626,605,000 3,799,341,000 3,874,039,000 4,041,405,000 3,888,968,000  3,974,409,000 4,023,053,000 3,960,070,000 4,006,033,000 4,037,536,000 4,056,756,000 4,390,800,000 3,665,890,000 3,703,943,000 4,262,139,000 4,384,586,000 4,352,736,000   
      liabilities and stockholders' equity
    		                            
      revolving credit facilities
    		       120,000,000                     
      stockholders' equity
    		                            
      preferred stock, 0.01 par value, 2,000 shares authorized, none issued at both june 30, 2023 and december 31, 2022
    		                            
      preferred stock, 0.01 par value, 2,000 shares authorized, none issued at both march 31, 2023 and december 31, 2022
    		                            
      preferred stock, 0.01 par value, 2,000 shares authorized; none issued at both december 31, 2022 and 2021
    		                            
      current portion of operating and financing lease liabilities - related party
    		          2,809,000 2,796,000 2,692,000 2,636,000 2,580,000 2,201,000 2,883,000 3,978,000 3,895,000 3,807,000 4,084,000 3,601,000 3,353,000 3,293,000 3,234,000    
      preferred stock, 0.01 par value, 2,000 shares authorized, none issued at both september 30, 2022 and december 31, 2021
    		                            
      preferred stock, 0.01 par value, 2,000 shares authorized, none issued at both june 30, 2022 and december 31, 2021
    		                            
      preferred stock, 0.01 par value, 2,000 shares authorized, none issued at both march 31, 2022 and december 31, 2021
    		                            
      financing lease right-of-use assets - related party
    		                 58,676,000 59,328,000 59,980,000 60,632,000 61,284,000 61,936,000 62,588,000 63,240,000    
      current portion of note payable - related party
    		                 1,000,000 1,000,000 1,000,000         
      financing lease liabilities - related party
    		                 60,193,000 60,490,000 60,782,000 61,069,000 61,463,000 61,719,000 61,990,000 62,256,000    
      preferred stock, 0.01 par value, 2,000 shares authorized; none issued at both december 31, 2021 and 2020
    		                            
      stockholders’ accumulated deficit
    		             -276,197,000               
      total amneal pharmaceuticals, inc. stockholders’ equity
    		             360,340,000               
      total stockholders’ equity
    		             366,973,000               
      total liabilities and stockholders’ equity
    		             3,939,664,000               
      related party payable - short term
    		              32,474,000 32,930,000 20,100,000  8,069,000 8,455,000         
      preferred stock, 0.01 par value, 2,000 shares authorized; none issued at both september 30, 2021 and december 31, 2020
    		                            
      preferred stock, 0.01 par value, 2,000 shares authorized; none issued at both june 30, 2021 and december 31, 2020
    		                            
      preferred stock, 0.01 par value, 2,000 shares authorized; none issued at both march 31, 2021 and december 31, 2020
    		                            
      redeemable non-controlling interest
    		                 11,804,000          11,858,000 
      stockholders' equity:
    		                            
      preferred stock, 0.01 par value, 2,000 shares authorized; none issued at both december 31, 2020 and 2019
    		                            
      preferred stock, 0.01 par value, 2,000 shares authorized; none issued at both september 30, 2020 and december 31, 2019
    		                            
      preferred stock, 0.01 par value, 2,000 shares authorized; none issued at both june 30, 2020 and december 31, 2019
    		                            
      current portion of note payable- related party
    		                    1,000,000        
      related party payable
    		                    11,195,000        
      preferred stock, 0.01 par value, 2,000 shares authorized; none issued at both march 31, 2020 and december 31, 2019
    		                            
      deferred tax asset
    		                       391,881,000 382,941,000 373,159,000 365,971,000 373,705,000 
      current portion of financing obligation - related party
    		                         266,000   
      related party payables
    		                     5,969,000 765,000 2,965,000 2,928,000 17,695,000 36,329,000  
      financing obligations - related party
    		                         39,083,000   
      deferred income taxes
    		                         1,178,000 1,761,000 2,491,000 
      liabilities under tax receivable agreement
    		                       193,499,000 193,499,000 192,884,000 195,820,000 194,825,000 
      preferred stock, 0.01 par value, 2,000 shares authorized; none issued at both december 31, 2019 and 2018
    		                            
      class b-1 common stock, 0.01 par value, 18,000 shares authorized at both december 31, 2019 and 2018; no and 12,329 shares issued at december 31, 2019 and 2018, respectively
    		                            
      financing obligation - related party
    		                            
      other liabilities
    		                      38,532,000 28,653,000 37,723,000    
      preferred stock, 0.01 par value, 2,000 shares authorized; none issued at both september 30, 2019 and december 31, 2018
    		                            
      class b-1 common stock, 0.01 par value, 18,000 shares authorized at both september 30, 2019 and december 31, 2018; no and 12,329 shares issued at september 30, 2019 and december 31, 2018, respectively
    		                            
      preferred stock, 0.01 par value, 2,000 shares authorized; none issued at both june 30, 2019 and december 31, 2018
    		                            
      class b-1 common stock, 0.01 par value, 18,000 shares authorized at both june 30, 2019 and december 31, 2018; none and 12,329 shares issued at june 30, 2019 and december 31, 2018, respectively
    		                            
      preferred stock, 0.01 par value, 2,000 shares authorized; none issued at both march 31, 2019 and december 31, 2018
    		                            
      class b-1 common stock, 0.01 par value, 18,000 shares authorized at both march 31, 2019 and december 31, 2018; 12,329 issued at both march 31, 2019 and december 31, 2018
    		                        123,000    
      members' equity, 189,000 units authorized, issued and outstanding at december 31, 2017
    		                            
      members' accumulated deficit
    		                            
      preferred stock, 0.01 par value, 2,000 shares authorized; none issued and outstanding at december 31, 2018
    		                            
      class b-1 common stock, 0.01 par value, 18,000 shares authorized; 12,329 shares issued and outstanding at december 31, 2018
    		                         123,000   
      liabilities and stockholders' equity / members' deficit
    		                            
      note payable and accrued interest-related party
    		                          78,126,000  
      current portion of long-term debt and financing obligations
    		                          121,694,000  
      long-term debt and financing obligations
    		                          2,675,108,000  
      related party payable- long term
    		                            
      stockholders' equity / members' deficit:
    		                            
      preferred stock, 0.01 par value, 2,000 shares authorized; none issued and outstanding at september 30, 2018
    		                            
      class b-1 common stock, 0.01 par value, 18,000 shares authorized; 12,329 shares issued and outstanding at september 30, 2018
    		                          123,000  
      stockholders' accumulated other comprehensive loss
    		                          -9,889,000 -6,502,000 
      total amneal pharmaceuticals, inc. stockholders' equity/ members' deficit
    		                          501,105,000 494,501,000 
      total stockholders' equity/ members' deficit
    		                          915,319,000 939,486,000 
      total liabilities and stockholders' equity/ members’ deficit
    		                          4,582,048,000 4,544,588,000 
      note payable-related party
    		                           77,549,000 
      current portion of financing obligations
    		                           251,000 
      related-party payables
    		                           14,875,000 
      long-term portion of financing obligations
    		                           39,220,000 
      related-party payable- long term
    		                            
      preferred stock, 0.01 par value, 2,000 shares authorized; none issued and outstanding at june 30, 2018
    		                            
      class b-1 common stock, 0.01 par value, 18,000 shares authorized; 12,329 shares issued and outstanding at june 30, 2018
    		                           123,000 
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.